Helicobacter pylori

The inflammatory activity in Helicobacter pylori infection is predominantly host-related.- Section VI: Helicobacter pylori and Gastritis.- 23 Helicobacter pylori gastritis - a global view.- 24 Unusual forms of gastric inflammation and their relationship to Helicobacter pylori infection.- 25 Can atrophic gastritis be diagnosed in the presence of Helicobacter pylori infection?.- 26 Mechanisms involved in gastric atrophy.- 27 Intestinal metaplasia: types, mechanisms of origin, and role in gastric cancer histogenesis.- 28 Long-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori-positive patients.- 29 Proton pump inhibitors do not accelerate the development of gastric atrophy in Helicobacter pylori gastritis.- 30 Autoimmune gastritis via mimicking does occur.- 31 Autoimmune gastritis and antigenic mimicking.- 32 Carditis and intestinal metaplasia of the cardia is reflux related.- 33 Carditis and cardia intestinal metaplasia are Helicobacter pylori-related.- 34 Is gastric metaplasia in Helicobacter pylori really gastric?.- Section VII: Helicobacter pylori and Clinical Consequences.- 35 Extragastric manifestations of Helicobacter pylori - are they relevant?.- 36 Peptic ulcer disease - the transitional zones are important.- 37 What causes Helicobacter pylori-negative non-NSAID-related ulcers?.- 38 From the pump to the helix.- 39 Mechanisms involved in the development of hypochlorhydria and pangastritis in Helicobacter pylori infection.- 40 Effect of Helicobacter pylori infection on gastric acid control using proton pump inhibitors.- 41 Rebound acid hypersecretion after acid-suppressive therapy.- 42 Gastric consequences of proton pump therapy and Helicobacter pylori eradication.- Section VIII: Helicobacter pylori, Dyspepsia and NSAIDs.- 43 Current concepts of dyspepsia: the role of the nervous system.- 44 How to explain outcome differences in dyspepsia studies.- 45 Helicobacter pylori eradication for dyspepsia is clinically useful.- 46 Dyspepsia is no indication for Helicobacter pylori eradication.- 47 Role of Helicobacter pylori infection in NSAID-associated gastropathy.- 48 Role of Helicobacter pylori in NSAID gastropathy: can Helicobacter pylori infection be beneficial?.- 49 Helicobacter pylori and non-steroidal anti-inflammatory drugs.- Section IX: Helicobacter pylori and 'Test-and-Treat' Strategies.- 50 The impact of a 'test-and-treat' strategy for Helicobacter pylori: the United States perspective.- 51 Test-and-treat strategy in dyspepsia - the European perspective.- 52 The impact of the 'test-and-treat' strategies for Helicobacter pylori infection - an Asian perspective?.- Section X: Helicobacter pylori and Gastric Malignancy.- 53 Rodent models for Helicobacter-induced gastric cancer.- 54 Helicobacter pylori and gastric cancer: the risk is real.- 55 Helicobacter pylori in gastric malignancy: role of oxidants, antioxidants and other co-factors.- 56 Gastric markers of pre-malignancy are not reversible.- 57 The case for the reversibility of gastric dysplasia/neoplasia.- 58 Evaluation of the long-term outcome of Helicobacter pylori-related gastric mucosa-associated lymphoid tissue (MALT) lymphoma.- Section XI: Treatment of Helicobacter pylori Infection.- 59 Current state-of-the-art management for Helicobacter pylori infection: global perspective.- 60 Guidelines for therapy of Helicobacter pylori infection - a world perspective.- 61 Bismuth triple and quadruple studies for Helicobacter pylori eradication in Canada.- 62 Approach to Helicobacter pylori infection in children.- 63 What role for clarithromycin in the treatment of Helicobacter pylori infection?.- 64 What is the role of bismuth in Helicobacter pylori antimicrobial resistance?.- 65 Risk factors for failure of Helicobacter pylori eradication therapy.- 66 Strategies for therapy failures: choice of 'back-up' regimen determined by primary treatment for Helicobacter pylori infection.- 67 Quadruple should be first-line therapy for Helicobacter pylori infection.- 68 Quadruple therapy should be secondline treatment for Helicobacter pylori infection.- 69 Helicobacter pylori infection: expectations for future therapy.- 70 A Helicobacter pylori vaccine is essential.- Section XII: Helicobacter Infections and the Future.- 71 The agenda for the microbiologist.- 72 The agenda for the immunologist.- 73 The agenda for the histopathologist.- 74 Helicobacter infections in the new millennium: the challenge for the clinician.